-
Mashup Score: 1
During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Pacritinib Improves Symptom Relief in Patients With Myelofibrosis Requiring RBC Transfusions | Blood Cancers Today - 1 month(s) ago
The phase III PERSIST-2 study compared symptom results from pacritinib with those of best available therapy and ruxolitinib.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
☑️ Pacritinib significantly improves symptom relief and transfusion independence in patients with #myelofibrosis requiring red blood cell transfusions. 📖 Read more from the study led by @mpndoc of @WashUHeme. #MPNsm ➡️ https://t.co/bzBZl3piHN https://t.co/Ye42CiR7pr
-
-
Mashup Score: 1
The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib failure or intolerance.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In the second-line, fedratinib showed its effectiveness in achieving spleen volume reduction while highlighting strategies for managing gastrointestinal adverse effects and thiamine deficiency in #myelofibrosis. #mpnsm https://t.co/GXyETGW0yf
-
-
Mashup Score: 2
During a Case-Based Roundtable® event, Nikolai Podoltsev, MD, PhD, discussed appropriate JAK inhibitor therapy options for a 62-year-old patient with myelofibrosis who had potentially declining hemoglobin and platelet counts.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Nikolai Podoltsev, MD, PhD, discussed appropriate JAK inhibitor therapy options for a 62-year-old patient with #myelofibrosis who had potentially declining hemoglobin and platelet counts. #MPNSM | @YaleMed https://t.co/K2HfTly3Gt
-
-
Mashup Score: 1Ruxolitinib Stands Out Among JAK2 Inhibitors for Myelofibrosis - 2 month(s) ago
Experts review the case of a 68-year-old woman diagnosed with primary myelofibrosis.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In a virtual tumor board discussion, experts review the case of a 68-year-old woman diagnosed with primary #myelofibrosis. #MPNSM | @Ramikomrokji @MoffittNews @GSTTnhs @bose_prithviraj @MDAndersonNews https://t.co/BYHJnRmrEU
-
-
Mashup Score: 29
Findings from FREEDOM2 support fedratinib as a second-line Janus kinase inhibitor option to reduce spleen size after ruxolitinib failure or intolerance in patients with myelofibrosis, and shows effective strategies for management of gastrointestinal adverse events and low thiamine concentrations through prophylaxis, monitoring, and treatment.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
NEW: the FREEDOM2 trial supports fedratinib as a second-line treatment after ruxolitinib compared with best available therapy in patients with #myelofibrosis. Fedratinib reduced spleen size and had manageable gastrointestinal adverse events #mpnsm https://t.co/lLQ5f9XrdG https://t.co/zuCglYve3c
-
-
Mashup Score: 2
During a Case-Based Roundtable® event, Nikolai Podoltsev, MD, PhD, discussed appropriate JAK inhibitor therapy options for a 62-year-old patient with myelofibrosis who had potentially declining hemoglobin and platelet counts.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Nikolai Podoltsev, MD, PhD, discussed appropriate JAK inhibitor therapy options for a 62-year-old patient with #myelofibrosis who had potentially declining hemoglobin and platelet counts. #MPNSM | @YaleMed https://t.co/K2HfTly3Gt
-
-
Mashup Score: 1
During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary #myelofibrosis. #MPNSM | @UPMCHillmanCC https://t.co/zMo2KjEFht https://t.co/GgbzQH2Eha
-
-
Mashup Score: 40How to treat Myelofibrosis - Discussion with Dr. Naveen Pemmaraju - 4 month(s) ago
In this episode of the Oncology Brothers podcast, we discussed the complexities of myelofibrosis, a challenging blood cancer. Dr. Naveen Pemmaraju from MD Anderson Cancer Center provided valuable insights into the diagnosis, prognosis, and management of myelofibrosis. Key points discussed included the importance of bone marrow biopsy, molecular analysis, and risk stratification using various scoring […]
Source: oncbrothers.comCategories: General Medicine News, Hem/OncsTweet-
👉👉👉Delighted to join .@OncBrothers for session topic on #Myelofibrosis | #MPNSM @sanamloghavi @hemedoc @BldCancerDoc @VivekSubbiah @Aiims1742 @Transplant_Doc @DrChrisHourigan @DavidSteensma @mpdrc @TapKadia @dgomezalmaguer @Daver_Leukemia https://t.co/zhvYYsmdXJ https://t.co/Jnx3MxdIKd
-
-
Mashup Score: 4
During a Case-Based Roundtable® event, Kristen Pettit, MD, discussed the use of pacritinib and momelotinib in cytopenic myelofibrosis in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Kristen Pettit, MD, (@kristenpettitmd) discussed the use of pacritinib and momelotinib in cytopenic #myelofibrosis in the second article of a 2-part series. #MPNSM https://t.co/Sno9J3BlSD
-
Kristen Pettit, MD, moderated a discussion on which disease features of #myelofibrosis are most challenging and when to use JAK inhibitors. #MPNSM | @kristenpettitmd https://t.co/vNqvXN2bNh